Pharmacy Times’ Post

View organization page for Pharmacy Times, graphic

82,988 followers

Giroctocogene fitelparvovec achieved non-inferiority and superiority for the total annualized bleeding rate (ABR) compared to routine Factor VIII (FVIII) replacement prophylaxis treatment from week 12 through at least 15 months, according to data from the AFFINE study (NCT04370054). Learn more: https://bit.ly/3YDjFLl

Giroctocogene Fitelparvovec Reduces Total Annualized Bleeding Rate for Hemophilia A

Giroctocogene Fitelparvovec Reduces Total Annualized Bleeding Rate for Hemophilia A

pharmacytimes.com

To view or add a comment, sign in

Explore topics